Author

Shankang Qu

Observed name: S Qu

Institution: Pepsi (United States)

Observed institutions: Becton Dickinson (United States), Pepsi (United States)

ORCID: 0009-0006-0109-6149

Observed ORCID: 0009-0006-0109-6149

OpenAlex ID: A5111775989

Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes

2010 · Laurence J. Hirsch, Michael A. Gibney, et al. · Current Medical Research and Opinion · 110

Skin‐Interfaced Microfluidic System with Machine Learning‐Enabled Image Processing of Sweat Biomarkers in Remote Settings

2022 · Lindsay B. Baker, Melissa S. Seib, et al. · Advanced Materials Technologies · 59

Percutaneous Lidocaine Administration Via a New Iontophoresis System in Children: Tolerability and Absence of Systemic Bioavailability

2003 · Gregory L. Kearns, Jeanellen Heacook, et al. · PEDIATRICS · 34

Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes

1999 · SA Ross, R Jamal, et al. · Practical Diabetes · 22

Change in liking following reduction in sweetness level of carbonated beverages: a randomized controlled parallel trial

2024 · Eunice Mah, Alison Kamil, et al. · Scientific Reports · 7

Evaluating the Acceptability and Utility of a Personalized Wellness App (Aspire2B) Using AI-Enabled Digital Biomarkers: Engagement Enhancement Pilot Study

2025 · Calissa J Leslie-Miller, Shellen R Goltz, et al. · JMIR Formative Research

Change in Liking Following Reduction in Sweetness Level of Carbonated Beverages: A Randomized Controlled Parallel Trial

2024 · Alison Kamil, Traci M Blonquist, et al. · Current Developments in Nutrition

Works count: 7

Citation count: 232

H-index: 5

I10-index: 4